Osteomyelitis Clinical Trial
Official title:
CERAMENT™|G - Bone Healing and Re-infection Prophylaxis
The surgical management of long bone infections is often challenging. Adequate surgical
debridement decreases the bacterial load, removes dead tissues, and gives a chance for the
host immune system and antibiotics to arrest infection. Adequate debridement may leave a
large bony defect. An appropriate management of the dead space is essential to arrest the
disease, and for maintenance of the bone's integrity. The current strategy includes the use
of antibiotic-loaded bone cement that can be used to sterilize and temporarily maintain the
dead space. The cement are usually removed after 2 to 4 weeks and replaced with a cancellous
graft harvested from the hip of the patient.
CERAMENT™| G is a CE-marked resorbable ceramic bone graft substitute composed by calcium
sulfate and calcium hydroxyapatite, intended to fill gaps and voids in the skeleton system
and to promote bone healing. The antibiotic gentamicin is included in the ceramic to prevent
colonization of gentamicin-sensible microorganisms in order to protect bone healing.
The aim of this study is to investigate the device absorption and bone in-growth of
CERAMENT™| G in a surgically revised bone infection. In addition, bone healing and infection
non-recurrence will be evaluated during 12 months of follow-up. The investigators expect a
treatment success of >90 % and that a similar bone healing will be obtained as with a
standard two-stage surgical procedure. In addition, the investigators believe that the use
of CERAMENT™| G will be of advantage for the patient as bone healing will be achieved with a
one-stage surgical procedure (in combination with antibiotic therapy), instead of a
two-stage procedure, thus decreasing potential surgery-related complications.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
Not yet recruiting |
NCT06402292 -
Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute
|
N/A | |
Completed |
NCT03846804 -
Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
|
N/A | |
Active, not recruiting |
NCT04945434 -
Clinical Effectiveness of S53P4 Bioactive Glass in Treatment of Long-bone Chronic Osteomyelitis
|
N/A | |
Recruiting |
NCT06084754 -
Effect of Pulsed Electromagnetic Field Stimulation on Localized Pediatric Osteomyelitis
|
N/A | |
Recruiting |
NCT05177107 -
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
|
Phase 2 | |
Recruiting |
NCT04554108 -
Acute Non-severe Osteomyelitis in Children - Outpatient Management Strategy With Oral Antibiotic Therapy Compared to a Standard Strategy With Conventional Hospitalization and Intravenous Antibiotic Therapy: a Randomized Open-label Non-inferiority Study With Bayesian and Medical-economic Analyses.
|
N/A | |
Terminated |
NCT01612962 -
Diagnostic Tests to Help Determine Osteomyelitis
|
N/A | |
Terminated |
NCT03091439 -
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
|
Phase 2 | |
Recruiting |
NCT04936958 -
RETR(Osteomyelitis)
|
||
Completed |
NCT03802552 -
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
|
Phase 1 | |
Completed |
NCT03559530 -
Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
|
||
Completed |
NCT00324922 -
Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis
|
Phase 3 | |
Completed |
NCT02084147 -
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
|
N/A | |
Terminated |
NCT02099240 -
Patients Response to Early Switch To Oral:Osteomyelitis Study
|
Early Phase 1 | |
Withdrawn |
NCT02344511 -
Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis
|
Phase 3 | |
Completed |
NCT00402064 -
The Influence of Bisphosphonates in the Oral Cavity in Children
|
N/A | |
Terminated |
NCT02168816 -
Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis
|
Phase 2 | |
Completed |
NCT02685033 -
Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis
|
Phase 2 | |
Completed |
NCT02335905 -
Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
|
Phase 1/Phase 2 |